Coreline Soft, a company specializing in AI-based medical imaging solutions, will participate in the 'AGILE DxRx 2025' conference taking place from April 3 to 5 in Bangkok, Thailand. The company plans to share its insights on the evolution and vision of its AI-based integrated thoracic diagnostic solution, based on its recent 3-in-1 product.

The 'AGILE DxRx 2025' conference aims to globally implement the discovery and treatment of early lung cancer and cardiovascular diseases. It is co-hosted by the Early Diagnosis and Treatment Foundation and the Institute for Diagnostic Accuracy (iDNA). This year's event will highlight international data showing that early diagnosis using chest CT is effective for the integrated diagnosis and mortality reduction of the 'BIG3' diseases: lung cancer, cardiovascular diseases, and chronic obstructive pulmonary disease (COPD). Economic and efficient screening introduction strategies will also be a major topic of discussion.

During the conference, Coreline Soft will share clinically validated insights on the early detection and intervention of lung cancer through AI-based chest CT analysis. Chang Ryung-woo, the Clinical Research Lead, will participate as a speaker to discuss the latest performance of AVIEW and share the current limitations and improvement direction of lung cancer early screening.

Coreline Soft’s AI software automates the analysis of chest CT images to facilitate the early detection of various thoracic diseases, including lung cancer. This technology assists healthcare professionals in making faster and more accurate diagnoses, ultimately contributing to improved patient outcomes. It also allows for cost-effective implementation across diverse medical environments, promising to revolutionize the early detection and treatment of lung cancer and related diseases globally.

AI at the Forefront of Global Public Health Innovation... "The Vision of AGILE and Coreline's Technology Align"

The role of AI is becoming increasingly vital. Discussions are expanding on how AI can enhance clinical efficiency and healthcare equity, from risk assessment to disease detection and post-intervention management.

Through its participation in AGILE, Coreline Soft emphasizes its strategy to expand the application of the AVIEW platform as a realistic solution that can be implemented even in countries with limited medical resources, going beyond technology and data-centric AI solutions. "The paradigm of early lung cancer diagnosis is evolving from a single-disease focus to an integrated lung health assessment, and the optimized AVIEW LCS Plus carries significant implications at the global clinical and policy levels," explained Kwon Ji-wan, Chief Technology Officer at Coreline Soft.

Meanwhile, Coreline Soft recently obtained FDA 510(k) certification for a version optimized for technology integration, accessibility, security, and stability, securing a foundation for global market entry along with European CE certification and the highest authoritative certifications in the medical AI field, including those for the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR).

Yeon Choul-woong 다른기사 보기